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Questions for Biotechs
REIVAC
Pierre Loulergue, Xavier Duval, Nezha Lenzi, Henri Laurichesse and Odile Launay; Email: odile.launay@cch.ap-hop-paris.fr 
All author are part of the REIVAC network.
How and when did your organization start, and where are you 
located?
The REIVAC, French Clinical Research Network in Vaccinology (in French 
REseau national d’Investigation en VACcinologie), was created in 2007 
by four clinical research sites working, partially or exclusively, in the 
field of vaccines. Each institution is experienced in both academic and 
industrial clinical research. The network is officially supported and 
sponsored by several public and private institutions (Inserm: National 
Institute of Health and Medical Research and GIP CeNGEPS: Group of 
Public Interest from the National Management trial Centre for Health 
Products). Since 2008, seven other clinical centers have joined the 
network. 
The coordination of the REIVAC is run by Dr. Odile Launay, infec-
tious diseases specialist and head of the Clinical Research Centre for 
Vaccinology Cochin Pasteur, located at Cochin Hospital in Paris.
What are the most critical problems in vaccine development in your 
field of interest?
One of our main hurdles in research is the vaccination of subjects 
whose immune system is altered by conditions such as extremes of 
age, HIV infection, immunosuppressive treatment for solid organ 
transplant, solid or hematologic cancers or autoimmune diseases. 
Protecting those subjects efficiently is a real challenge today, and 
research clinicians have to work closely with scientists and companies 
in order to develop more immunogenic vaccines and improve routes 
of vaccine administration.
From an organizational point of view, clinical research in vac-
cinology requires more international collaborations between clinical 
research centers. Working with other countries requires important 
funding, and public grants are still rare.  
What is the mission of your organization? 
The REIVAC’s mission is to improve the attractiveness of France for 
the implementation of preventive and therapeutic vaccine trials, from 
preclinical to clinical phases, and to link up scientists and physicians 
as well as industries and academic institutions to develop exploratory 
research in vaccinology.
How does your organization facilitate vaccine development?
Our strengths are to have a centralized coordination team, closely 
working with a steering scientific committee, which gives REIVAC the 
power to answer solicitations from industrial companies or academic 
research teams with great reactivity. We also facilitate financial and 
hospital agreements validation to reduce the administrative delays. 
Moreover, the REIVAC can provide scientific, clinical and technical 
expertise in vaccines to ensure high standards for trials, and the clinical 
research centers composing the network may ease the recruitment of 
healthy volunteers and/or patients. Optimal safety is guaranteed, espe-
cially for early phases, by adapted procedures and experienced teams.
How does your organization engage national and international 
resources committed to vaccine research?
REIVAC is funded by the GIP CeNGEPS and the Inserm. We receive funds 
annually, after validation of our activity reports. Those funds allow us 
to hire the coordination team and several clinical research assistants 
located in the different clinical centers of REIVAC.
The primary role of these research assistants is to help recruit partic-
ipants. The coordination team coordinates the network; it is composed 
of a clinical study coordinator, a clinical research pharmacist, a quality 
engineer and a clinical research assistant. We also organize national 
scientific meetings where scientists, clinicians and industrials can share 
their works and build new clinical studies.
What important partnerships does your organization have?
We are working with academic partners such as Inserm, Institut Pasteur, 
Paris Descartes University, the CEA (French Alternative Energies and 
Atomic Energy Commission), the ANRS (French AIDS Research Agency); 
and also pharmaceutical companies like GSK Biologicals, Sanofi-
Pasteur, Merck, Sanofi-Pasteur-MSD, Transgene, and Becton Dickinson. 
What is your function at your organization?  
As founding members of REIVAC we form the steering committee and 
provide the strategic directions of the network.  
What were your “highlights“ in recent vaccine research, develop-
ment, or use?
The REIVAC has been strongly involved in studies of influenza vac-
cination with the H1N1 pandemic vaccine and the seasonal vaccine. It 
is also involved in a clinical trial with a Staphylococcus aureus vaccine 
in adult patients scheduled for cardiothoracic surgery and clinical 
trials with an adjuvant immunotherapy using an antigen specific for 
melanoma cancer. 
Currently the REIVAC is in clinical trials for a zoster vaccination, 
to evaluate its efficacy in immunocompromised patients; but also in 
therapeutic vaccine in patients with lung cancer.
What areas or topics does your organization currently focus on? 
The REIVAC is focusing on early phase clinical trials and studies aiming 
at increasing the immunogenicity of vaccines in immunocompromised 
hosts.  
What are your main goals for the next five years? 
Our objectives are to improve, harmonize and facilitate the recruitment 
of volunteers in our clinical centers; to generate more vaccine trials in 
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France and in the European Community; to evaluate innovative con-
cepts resulting from the basic science; to set up a biobank; and finally 
to extend scientific and medical knowledge in vaccinology, especially in 
immunocompromised patients. 
For more information, please visit: www.reivac.com
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